Article Information
History
- February 8, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Haiquan Li, PhD+,*,1,
- Edwin Baldwin, BS+,1,
- Xiang Zhang, MS1,
- Colleen Kenost, EdD, MPH4,
- Wenting Luo, MS1,
- Elizabeth A. Calhoun, PhD2,
- Lingling An, PhD1,
- Charles L. Bennett, MD, PhD*,3 and
- Yves A. Lussier, MD*,4
- 1Department of Biosystems Engineering, University of Arizona, Tucson, Arizona
- 2Department of Population Health, University of Kansas Medical Center, Westwood, Kansas
- 3Department of Clinical Pharmacy and Outcomes Sciences, University of South Carolina, Columbia, South Carolina
- 4Cancer Center and Department of Medicine, University of Arizona, Tucson, Arizona
- ↵*Corresponding authors Correspondence should be addressed to: Haiquan Li haiquan{at}arizona.edu, Biosystems Engineering, The University of Arizona 1177 E 4th St., Tucson, Arizona 85721, Phone: (520) 621-1890, Charles L. Bennett bennettc{at}cop.sc.edu, Clinical Pharmacy and Outcomes Sciences, University of South Carolina, 715 Sumter Street, Columbia, SC 29208, Phone: (803) 777-9004, Yves A. Lussier yves{at}arizona.edu, University of Arizona Health Sciences, 1657 E. Helen St., Tucson, Arizona 85721, Phone: (520) 626-3968
↵+ equally contributed
Posted February 08, 2021.
COVID-19 increases age- and sex-controlled 21-day fatality rates for patients with melanoma, hematologic malignancies, uterine cancer, or kidney cancer
